Overall, these results suggest that 0.7% ISO treatment attenuates ZY-induced inflammatory responses in KCs by reducing p38 MAPK phosphorylation and p38 MAPK-regulated NF-κB activation. The gene discussed is NFKB1; the disease is dry eye syndrome.